**13. Conclusion**

Among the various pathophysiology suggested for SCARs, T cells play a major role in the occurrence of delayed hypersensitivity reactions presenting as SCAR variants. There is a need to select structurally different classes of antibiotics in case of antibiotic-induced severe cutaneous adverse reaction (SCAR) to avoid recurrence. Furthermore, there is a need to conduct research and explore the immune mechanism of viral-drug-gene interaction and develop drugs to modulate T cells/ other cell lineages/novel therapeutic targets. Animal models for SCAR variants may be an important step toward the development of new drugs but are understudied. Nevertheless, rational use of antibiotics should be promoted as well as implemented into practice by consumers and health care physicians. The important concern with Immunomodulators and targeted therapies is associated with long-term sequelae such as immune reactive inflammatory syndrome and polyglandular autoimmune syndrome III. Validation of more prognostic HLA and other biomarkers for guiding therapy may help to prevent the occurrence of scars. There is a need to develop multicentric, multi-ethnic, and multi-regional registries that will enable us to gather clinical and demographic profiles, along with histopathological, genomic, proteomic, and metabolomic evaluation supplemented with a data mining approach for a better understanding of signals generated. The metabolomic approach may be helpful to detect the drug or its metabolite may be the causative factor for SCAR severity.
